When taken according to label and dosing instructions to relieve cough symptoms, medicines containing DXM produce few side effects and have a long history of safety and effectiveness. When abused, DXM can cause side effects including mild distortions of color and sound, hallucinations and loss of motor control. Also, many OTC medicines that contain DXM may also contain other ingredients such as antihistamines, analgesics or decongestants. High doses of these combination medicines can significantly increase the harmful effects such as potentially fatal liver injury, cardiovascular effects and over-sedation. OTC cough medicine is also sometimes abused with other drugs, including alcohol, which can cause additional harmful effects.
The data described below reflect exposure to ALIMTA in 168 patients that were fully supplemented with folic acid and vitamin B12. Median age was 60 years (range 19 to 85 years); 82% were men; 92% were White, 5% were Hispanic or Latino, % were Asian, and <1% were other ethnicities; 54% had KPS of 90-100. The median number of treatment cycles administered was 6 in the ALIMTA/cisplatin fully supplemented group and 2 in the ALIMTA/cisplatin never supplemented group. Patients receiving ALIMTA in the fully supplemented group had a relative dose intensity of 93% of the protocol-specified ALIMTA dose intensity. The most common adverse reaction resulting in dose delay was neutropenia.
It is not clear what sort of risk the possibility of conferring antibiotic resistance to bacteria presents. No one has ever observed bacteria incorporating new DNA from the digestive system under controlled laboratory conditions. The two types of antibiotic resistance genes used by biotechnologists are ones that already exist in bacteria in nature so the process would not introduce new antibiotic resistance to bacteria. Never the less it is a concern and the FDA is encouraging biotechnologists to phase out the practice of using antibiotic resistance genes (GEO-PIE website).